Related Experiment Videos

Acetylcysteine and contrast agent-associated nephrotoxicity

Carlo Briguori1, Fiore Manganelli, Pierfranco Scarpato

  • 1Laboratory of Interventional Cardiology and Department of Cardiology, Clinica Mediterranea, Via Orazio 2, I-80121 Naples, Italy. cabrig@hotmail.com

Insights

Prophylactic acetylcysteine with hydration may help prevent contrast-induced kidney injury, especially with low contrast doses. However, the total contrast amount was the main predictor of nephrotoxicity in this study.

Area of Science:

  • Nephrology
  • Radiology
  • Pharmacology

Background:

  • Contrast media administration can precipitate acute kidney injury (AKI), sometimes necessitating dialysis.
  • Patients with pre-existing renal impairment are at higher risk for contrast-induced nephropathy (CIN).

Purpose of the Study:

  • To evaluate the efficacy of prophylactic acetylcysteine (N-acetylcysteine) combined with hydration versus hydration alone in preventing CIN.
  • To identify predictors of CIN in patients undergoing angiography.

Main Methods:

  • A randomized controlled trial involving 183 patients with renal impairment undergoing angiography.
  • Patients received either intravenous saline with oral acetylcysteine or intravenous saline alone before and after contrast dye administration.
  • Renal function was assessed by serum creatinine levels 48 hours post-procedure.

Main Results:

  • No significant difference in overall CIN rates between the acetylcysteine and control groups (6.5% vs. 11%).
  • However, in the subgroup receiving a low contrast dose (<140 ml), acetylcysteine significantly reduced CIN (0% vs. 8.5%, p=0.02).
  • Multivariate analysis identified the volume of contrast agent, not acetylcysteine, as a significant predictor of CIN (OR 2.58).

Conclusions:

  • Prophylactic acetylcysteine did not significantly reduce overall CIN rates in patients with renal impairment.
  • The amount of contrast agent administered was the primary predictor of contrast-induced nephrotoxicity.
  • Acetylcysteine may offer a protective benefit in patients receiving low contrast volumes.
Abstract

Related Concept Videos